Gepotidacin

Gepotidacin
Clinical data
Trade names	Blujepa
Other names	GSK2140944
AHFS/Drugs.com	Monograph
MedlinePlus	a625059
License data	US DailyMed: Gepotidacin;
Routes of; administration	By mouth
ATC code	J01XX13 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name (2R)-2-({4-[(3,4-Dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2a,5,8a-triazaacenaphthylene-3,8-dione;
CAS Number	1075236-89-3;
DrugBank	DB12134;
ChemSpider	34982930;
UNII	DVF0PR037D; 5P7X0H2O6B;
KEGG	D10878; D10879;
ECHA InfoCard	100.249.088
Chemical and physical data
Formula	C24H28N6O3
Molar mass	448.527 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c1cc(=O)n2c3c1ncc(=O)n3[C@@H](C2)CN4CCC(CC4)NCc5cc6c(cn5)OCCC6;
	InChI InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m1/s1; Key:PZFAZQUREQIODZ-LJQANCHMSA-N;

Gepotidacin, sold under the brand name Blujepa, is an antibiotic medication used for the treatment of urinary tract infection.^[1] Gepotidacin is a triazaacenaphthylene bacterial type II topoisomerase inhibitor.^[1]^[2] It is used as the salt gepotidacin mesylate, and is taken by mouth.^[1]

Gepotidacin was approved for medical use in the United States in March 2025.^[1]^[3]

^ ^a ^b ^c ^d ^e "Blujepa- gepotidacin tablet, film coated". DailyMed. 25 March 2025. Retrieved 2 April 2025.
^ Biedenbach DJ, Bouchillon SK, Hackel M, Miller LA, Scangarella-Oman NE, Jakielaszek C, et al. (January 2016). "In Vitro Activity of Gepotidacin, a Novel Triazaacenaphthylene Bacterial Topoisomerase Inhibitor, against a Broad Spectrum of Bacterial Pathogens". Antimicrobial Agents and Chemotherapy. 60 (3): 1918–1923. doi:10.1128/aac.02820-15. PMC 4776004. PMID 26729499.
^ Fick M, Sneha SK, Sunny ME (2025). "FDA approval". Reuters.